Monitoring patients taking oral carbonic anhydrase inhibitors.
Although no prospective studies have been done and no recommendations can be reasonably evidenced based, we believe that our "alternative views" are reason-able, taking into account the serious nature of aplastic anemia and its more favorable prognosis when this disorder is treated early. Because aplastic anemia represents only about one half of possible CAl blood dyscrasias, early recognition of non-aplastic anemia dyscrasias alone Justifies hematologic screening.
Fraunfelder
F T
FT
Bagby
G C
GC
D000284:Administration, Oral; D000741:Anemia, Aplastic / Q000139:chemically induced / Q000517:prevention & control; D001853:Bone Marrow / Q000187:drug effects; D002257:Carbonic Anhydrase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D016903:Drug Monitoring; D006403:Hematologic Tests; D006801:Humans
D002257:Carbonic Anhydrase Inhibitors